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Abstract
The effects of microgravity conditions on neurovestibular, cardiovascular, 
musculoskeletal, bone metabolic, and hemato-immunological systems are 
described. We discuss “space motion sickness,” sensorimotor coordination disor-
ders, cardiovascular deconditioning, muscular atrophy, bone loss, and anemia/
immunodeficiency, including their causes and mechanisms. In addition to the 
previously described deconditioning, new problems related to microgravity, 
spaceflight-associated neuro-ocular syndrome (SANS), and structural changes of 
the brain by magnetic resonance imaging (MRI) are also explained. Our proposed 
countermeasure, artificial gravity produced by a short-arm centrifuge with 
ergometric exercise, is also described in detail, and we confirmed this system to be 
effective in preventing the abovementioned deconditioning caused by micrograv-
ity exposure.
Keywords: microgravity, neurovestibular, neural plasticity, cardiovascular, 
musculoskeletal, bone metabolism, hematology and immunology
1. Introduction
Outer space offers several abnormal and/or unique environmental conditions, 
including microgravity, vacuum/hypovaria, acceleration, extreme temperature, space 
debris, space radiation, and confinement/isolation. As the latter four conditions may 
be mitigated by spacecraft engineering (i.e., pressurization and the bulkhead), we 
focused on microgravity and its effects on human physiology [1–8].
In spaceflight, astronauts face three periods of physiological adaptation induced 
by changing gravity: (1) changes upon entry to microgravity (initial adaptation), 
(2) changes after prolonged exposure to microgravity, and (3) readaptation to 1 G 
gravity on Earth after returning from space. Body systems influenced by micro-
gravity are the neurovestibular, cardiovascular, musculoskeletal, bone metabolic, 
and immuno-hematological systems. The changes associated with these systems 
occur during the adaptation phases outlined above. We will briefly discuss each of 
these body systems.
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2. Neurovestibular system
2.1 Space motion sickness
How do we humans sense our relative positions in three-dimensional space? 
There are three sensory systems in the human body that help us define position: the 
visual, somatosensory, and vestibular systems. Most of the information from the 
outside world is processed by the visual system, but the combination of somatosen-
sory and vestibular systems from the inner body helps define the positional status.
The vestibular organs include the otolith organs and semicircular canals. The 
otolith organs, saccules (sagittal direction) and utriculi (horizontal direction), 
sense linear acceleration. The semicircular canals, anterior, posterior, and horizon-
tal, detect angular velocity of the head. The vestibular organs in the inner ear detect 
and measure linear and angular acceleration. These responses—already a complex 
set of signals—are further integrated with visual and proprioceptive inputs.
Exposure to microgravity alters some of these input signals, leading to misinter-
pretation and inadequate responses by the brain. This may cause vertigo, nausea, 
vomiting, appetite loss, headache, pallor, etc. As the symptoms are like those of 
motion sickness, this set of symptoms is termed “space motion sickness,” but unlike 
conventional motion sickness, antiemetic drugs cannot suppress the symptoms of 
space motion sickness. Approximately 60–80% of astronauts develop the symptoms 
within 2 or 3 days after launch. Space motion sickness is considered important 
because of its potential impact on the astronauts’ operational performance.
Although sensory misinterpretation may play a role in space motion sickness, its 
exact mechanism remains unknown. There are, however, several hypotheses:  
(1) sensory conflict, (2) fluid shift, (3) otolith asymmetry, and (4) orientation 
adaptation [9, 10].
The sensory conflict hypothesis suggests that loss of tilt-related otolith upon 
entry into microgravity causes a conflict between actual and anticipated signals 
from sense organs subserving spatial orientation. Such sensory conflicts are thought 
to induce motion sickness in other environments.
The fluid shift hypothesis suggests that space motion sickness results from the 
caudad fluid shifts, which in turn result from the hydrostatic pressure gradients in 
the lower body to the thoracic cavity or to the cranial cavity when entering micro-
gravity. The cephalad fluid shift leads to visible puffiness in the face and is thought 
to increase the intracranial pressure, the cerebrospinal fluid pressure, or the inner 
ear fluid pressure, altering the response properties of the vestibular receptors and 
inducing space motion sickness.
The otolith asymmetry hypothesis is based on the theory that a mass difference 
in otolith between the left and right ear is the origin of space sickness and that there 
is interindividual susceptibility.
The otolith adaptation theory, or otolith tilt-translation reinterpretation theory, is 
the theory that space motion sickness is caused during the process of the brain learning 
to reinterpret novel otolith quasi-static signals to represent linear acceleration in space 
rather than the usual interpretation of tilt relative to the vertical direction on Earth.
Until now, it was unclear which of these theories (if any) was most likely. 
However, evidence from Space Shuttle missions suggests that the otolith asymmetry 
and otolith adaptation theories are unlikely.
2.2 Countermeasures for space motion sickness
In the Shuttle program and in the case of the International Space Station 
(ISS), the most commonly used countermeasure for space motion sickness is 
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pharmacotherapy. Dornhoffer [11] reported the effects of four drug countermea-
sures (lorazepam, meclizine, promethazine, and scopolamine) for alleviating 
motion sickness induced by vestibular stimulation with a rotary chair and found 
that scopolamine was the only countermeasure to significantly change the mean 
duration of rotation compared with the placebo (p < 0.008), with a > 40% increase 
in rotation time.
In the Shuttle study, administration of promethazine at 20–50 mg was recom-
mended by intramuscular injection or suppository. In the ISS study, meclizine and 
dimenhydrinate with cinnarizine were hypothesized to affect the medial vestibular 
nucleus. Promethazine is a vestibular suppressor, but a more recent report [12] 
demonstrated that d-amphetamine counters this suppression and inhibits the 
effects of fatigue on the saccadic reaction time.
We propose that artificial gravity is also effective in preventing space motion 
sickness because constant gravity on the otolith is effective against all four etiologies 
of this maladaptation.
3. Cardiovascular system
3.1 Effects of microgravity in the cardiovascular system
The changes in the cardiovascular system begin solely with the fluid shift associ-
ated with microgravity, followed by the decreased circulatory blood volume, cardiac 
size, and aerobic capacity, and the most prominent symptom, postflight orthostatic 
intolerance. These symptoms are generically known as “cardiovascular decondition-
ing” [13–17].
When the spacecraft reaches low Earth orbit (LEO), body fluids move from the 
lower body to the thorax, which is associated with the increase in the intraocular 
pressure and morphological alterations in the central nervous system, demon-
strated by changes in the magnetic resonance imaging (MRI).
As a result of fluid shift, the leg volume decreases and the face becomes puffy. 
The leg volume decreases by 1 L, whereas subcutaneous tissue at the forehead 
thickens by as much as 7% compared with in the preflight supine position. The 
pulmonary capillary blood volume increases by approximately 25%, and intraocular 
pressure can nearly double. Fluid shift increases the cardiac volume and stroke 
volume at the beginning of the spaceflight (first 24 to 48 hours), but over time, the 
heart rate, stroke volume, and cardiac output stabilize to the preflight sitting level. 
The arterial blood pressure slightly decreases compared with the preflight level. 
Compared with “space motion sickness,” cardiovascular and fluid balance adapta-
tion is gradual. The symptoms appear in 3–5 days and disappear after 1–2 weeks, 
causing facial edema, nasal stiffness, heavy headedness, papilledema, or jugular 
vein dilatation. These symptoms upon exposure to microgravity disappear at most 
2 weeks after the reduction in circulatory plasma volume [13–17].
The cardiovascular changes in actual spaceflight differ from those in stimula-
tions such as head-down bedrest or dry immersion. First, the volume of fluid shift 
is much larger than the orthostatic change from the supine to upright positions. 
The fluid volume loss during simulated microgravity (e.g., head-down bedrest or 
dry immersion) is less than 50% of that observed in actual spaceflight. Second, the 
central venous pressure measured during spaceflight does not increase as much as in 
head-down bedrest. Third, the diuresis caused during simulated microgravity is to a 
lower degree.
Then what is the cause of reduced blood volume after adaptation to micro-
gravity? Diedrich et al. [18] explained the reduced blood volume in space as (1) 
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a negative balance 2010 of decreased fluid intake and smaller reduction of urine 
output; (2) fast fluid shifts from the intravascular to interstitial spaces as a result of 
lower transmural pressure after reduced compression of all tissues by gravitational 
forces, especially of the thorax cage; and (3) fluid shifts from intravascular to 
muscle interstitial spaces because of lower muscle tone required to maintain body 
posture, and the attenuated diuresis during space flight is due to increased retention 
after stress-mediated sympathetic activation during the initial phase of space flight.
3.2 Decrease in the circulatory blood volume
The centralization of body fluid induces dehydration to adapt to the micrograv-
ity environment. The cephalad fluid shift causes an increase in venous return and 
marked increase in the stroke volume, inducing the alterations in the autonomic 
and endocrine systems to control the cardiovascular system.
On the first day of microgravity exposure, urine volume does not increase, but 
the circulatory blood volume suddenly decreases by 17%, probably due to the shift 
of water from the intravascular to the interstitial spaces and finally to the intracel-
lular space. This induces an increase in the hematocrit level, which suppresses 
erythropoietin production and reduces the erythrocyte volume. Reductions in the 
circulatory plasma volume and erythrocyte volume equal an 11% reduction in the 
total blood volume, and this stabilizes the central blood volume to a new equilib-
rium, which nearly equals the central blood volume in the standing position at 1 G 
on Earth.
Upon the above alterations, the autonomic nervous system stabilizes the blood 
pressure by suppressing the sympathetic functions and activating the vagal func-
tions by reducing the heart rate and suppressing muscle sympathetic nerve activity. 
Alterations include suppression of vasopressin by the Henry-Gauer reflex, facilita-
tion of α-natriuretic peptide secretion, and suppression of the renin-angiotensin-
aldosterone system, all of which facilitate urination. Thus, centralized body fluid 
is excreted, accounting for 10–15% of the circulatory blood volume, increased 
hematocrit level, and adaptation of the cardiovascular system 5–7 days after micro-
gravity exposure. This ameliorates the facial edema and jugular distension. This 
adaptation causes cardiovascular deconditioning, including orthostatic intolerance, 
after returning to 1 G on Earth.
3.3 Reduced heart size
Once exposed to microgravity, the volume and pressure stimuli disappear. 
Constant postural change of lying down from upright standing on Earth loads 
intermittent volume on the heart, which ceases during microgravity. In addition, 
microgravity reduces the overall pressure load on the heart depending on the con-
tent of the countermeasure program. The mean arterial pressure slightly decreases. 
During spaceflight, the myocardial volume decreases by 8–10%.
3.4 Cardiovascular system after stabilization
After adaptation to microgravity, the cardiovascular system stabilizes, and the 
blood pressure is either unchanged or slightly lower [19]. Ambulatory blood pres-
sure recording for 24 hours in eight astronauts revealed that the systolic, diastolic, 
and mean arterial pressures (mean ± se) in space were reduced by 8 ± 2 mmHg 
(p = 0.01; ANOVA), 9 ± 2 mmHg (P < 0.001), and 10 ± 3 mmHg (p = 0.006), 
respectively, with a maintained nocturnal dip of 8 ± 3 mmHg (p = 0.015). The 
cardiac stroke volume and output increased by 35 ± 10% and 41 ± 9% (p < 0.001), 
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respectively, the heart rate and catecholamine concentrations were unchanged, and 
systemic vascular resistance was reduced by 39 ± 4% (p < 0.001).
3.5 Alteration of aerobic exercise capacity
Microgravity exposure reduces the circulatory blood volume; however, the 
maximal oxygen uptake is maintained after a short duration of spaceflight. 
During long-term spaceflight, the aerobic capacity decreases without countermea-
sures, but aerobic exercise training can maintain it, although standard exercise 
only markedly reduces the postflight maximal oxygen uptake. After a short dura-
tion of spaceflight (9–14 days), the maximal oxygen uptake decreased by 22%, 
probably due to decreases in the maximal stroke volume and maximal cardiac 
output without alterations in the maximal heart rate, blood pressure, or whole-
body arteriovenous oxygen. This decrease in maximal oxygen uptake is believed to 
be due to the decreases in intravascular blood volume, stroke volume, and cardiac 
output.
As crew members are expected to work on the Moon/Martian surface, and they 
are exposed to extensive heat stress in the extravehicular suits, this aerobic capacity 
is considered to be significant after landing on the Moon/Mars.
3.6 Alterations in sympathetic neural traffic under microgravity
Sympathetic neural traffic indirectly measured by the plasma noradrenaline 
level has been reported to increase during spaceflight from the preflight control 
level [14, 20], and vagal activity estimated by power spectral analysis of heart rate 
variability was reduced after long-term spaceflight [21, 22].
Microneurographically recorded neural traffic in humans is known to be muscle 
and skin sympathetic nerve activity (MSNA and SSNA), and MSNA controls the 
vasomotor function of the muscular bed, responding to blood pressure changes 
against gravitational stress [23–25]. MSNA was suppressed during exposure to 
short-term microgravity induced by parabolic flight [26], mild lower body positive 
pressure (10–20-mmHg LBPP) [15], and thermoneutral head-out water immersion 
[27] responding to the loading or unloading of cardiopulmonary receptor-stimu-
lated cephalad fluid shift. On the other hand, MSNA was increased after exposure 
to long-term microgravity in spaceflight and its simulation induced by dry immer-
sion [28] or 6° head-down tilt bedrest [17] due to different mechanisms, including 
plasma volume loss, changes in baroreflex, and vascular compliance.
3.7 Postflight orthostatic intolerance
Orthostatic intolerance is usually observed after returning to 1 G on Earth. The 
definition of orthostatic intolerance usually includes simple syncope, lightheaded-
ness, or >20-mmHg reduction in systolic blood pressure.
Astronauts usually notice orthostatic intolerance during prolonged upright 
standing rather than while standing up. Just before fainting, they sometimes have 
tachycardia, suggesting that they have postural orthostatic tachycardia syndrome 
(POTS). This phenomenon is due to a state in which fluid shift easily triggers 
tachycardia, which also easily triggers Bezold-Jarisch reflex, and the vagal response 
suppresses the systolic blood pressure. Although all astronauts stood upright for 
10 min, 63% were unable to finish the stand test in 10 min.
Less important factors for postflight orthostatic intolerance are reduced compli-
ance of the lower legs, reduced baroreflex sensitivity, and increased basal sympa-
thetic tone.
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Reduction of the circulatory blood volume is the most important factor for 
postflight orthostatic intolerance. The decrease in stroke volume after spaceflight 
reflects this circulatory blood volume loss. Although this is the main cause, the 
recovery of circulatory blood volume to the normal state is not complete. The crew 
members are recommended to take 8 g of salt and 1 L of water, which ameliorates 
the orthostatic tolerance, albeit not completely.
Another factor is the limitation by vasoconstriction. The postflight blood 
pressure of non-finishers cannot be increased by the total peripheral resistance 
compared with the preflight state. During the postflight upright standing 70° tilt 
test, the total peripheral resistance cannot increase despite activation of muscle 
sympathetic nerve activity, probably due to the alterations in venoarterial reflex and 
smooth muscle atrophy of the resistant vessels. Overall, circulatory blood volume 
reduction and attenuated vasoconstriction are the main factors for orthostatic 
intolerance.
3.8 Cardiovascular deconditioning
What is the cause of this cardiovascular deconditioning? NASA’s criteria of 
orthostatic intolerance are (1) presyncopal symptoms (pallor, cold sweat, nausea, 
blackout, and fainting), (2) gradual systolic blood pressure decrease <80 mmHg, 
(3) sudden systolic blood pressure decrease >15 mmHg, or (4) sudden heart rate 
decrease >15 bpm while on the 70° tilt bed for 15 min. A recent report stated that 
65% of astronauts satisfied these criteria. Previously, this cardiovascular decon-
ditioning was considered to be solely due to circulatory fluid loss, but other causes 
have also been explored.
In addition to the decrease in circulatory blood volume, other causes, i.e., altered 
arterial baroreflex gain, altered leg venous volume, easy fluid pooling in the space 
of atrophied skeletal muscles, attenuated muscle pump effects due to skeletal 
muscle atrophy, hypersensitivity of β-adrenergic receptors, and altered influence 
of vestibular (especially otolith) input, have been considered. Moreover, increased 
venous permeability of lower leg vessels and attenuated cardiopulmonary volume 
receptor reflex after −6° head-down tilt for 14 days were observed in our bedrest 
experiment. These changes are not the only cause of cardiovascular deconditioning, 
and multiple factors act in concert.
3.9 Spaceflight-associated neuro-ocular syndrome (SANS)
Several physiological and pathological neuro-ocular findings in astronauts/
cosmonauts during and after long-term spaceflight, including hyperoptic shifts up 
to +1.75 diopters, optic disc edema (swelling), globe (eyeball) flattening, choroidal 
folds, and “cotton wool” spots in the fundus oculi, have been reported [29]. These 
findings have been documented as spaceflight-associated neuro-ocular syndrome. 
NASA has investigated the clinical, ultrasound, optical coherence tomography 
imaging, and fundus oculi findings of the above symptoms. In 2016, out of 47 or 64 
astronauts examined, approximately 10 developed SANS (disc edema in 10/64, cot-
ton wool spot in 7/64, choroidal folds in 11/47, globe flattening in 12/47, and refrac-
tive error in 9/47). It is unlikely that the duration of spaceflight is unrelated [30].
The exact cause of SANS has not been clarified, but its development is likely 
related to the increase in intracranial pressure due to the cephalad fluid shift. The 
increase in intracranial pressure is not necessarily due to microgravity exposure, 
but some percentage of astronauts had intracranial pressure change and developed 
SANS [29, 30].
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Several countermeasures, e.g., lower body negative pressure, thigh cuffs, an 
impedance threshold device (ITD), vitamin B group administration, and artificial 
gravity, have been considered and are under trial. NASA and collaborating research-
ers continue to investigate SANS in preparation for future manned missions to 
space, including continued trips to the ISS, deep space gateway missions, a return to 
the Moon or Moon base, or a Martian expedition.
3.10 Brain structural plasticity during spaceflight
In 2016, structural changes in the brain during spaceflight were reported.  
Koppelmans et al. [31] evaluated retrospective longitudinal T2-weighted MRI scans 
and balance data from 27 astronauts (13, ~2-week Shuttle crew members, and 14, 
~6-month ISS crew members) to assess spaceflight effects on brain structure. They 
observed extensive volumetric gray matter decreases, including large areas covering 
the temporal and frontal poles and around the orbits, and the effects were larger 
in ISS members than in Shuttle crew members. There were also bilateral focal gray 
matter increases within the medial primary somatosensory and motor cortex.
In 2017, a review on these MRI changes associated with spaceflight (actual 
or simulated) was reported. Van Ombergen et al. [32] discussed neuroplastic 
changes in the central nervous system and concluded that the cerebellum, cortical 
motor areas, and vestibular-related pathways are highly involved, demonstrating 
that these brain regions are indeed affected by actual and simulated spaceflight. 
Structural studies are now in progress, and functional relationships are under 
investigation. Long-term studies will be necessary to clarify the mechanism.
3.11 Effects of artificial gravity
We tested an intermittent short-arm centrifuge of 1.4 G with 60-W ergometric 
exercise with a step-up increase of 0.2 G and 15 W, respectively, for 30 min every 
day for 21 days during −6° head-down bedrest [33]. The circulatory blood volume 
was reduced by 20% in the control subjects, but no reduction was observed in the 
countermeasure subjects. Cardiac output and stroke volume were not changed 
in the countermeasure subjects, but they decreased in the control subjects. The 
baseline level of muscle sympathetic nerve activity (MSNA) was not changed in the 
countermeasure subjects, but it increased in the control subjects.
Therefore, everyday ergometric exercise under artificial gravity maintains the 
preflight cardiovascular state without adapting to microgravity.
4. Musculoskeletal system
4.1 Mechanism of muscle loss under microgravity
The first muscular measurements were performed in Skylab and Space Shuttle 
missions by the United States and in Salyut and Mir by the Soviet Union [34–37]. 
The most prominent muscle loss was observed in the calf muscle (the soleus and 
gastrocnemius) after a few weeks in space. The muscle loss exhibited interindi-
vidual variation, but the maximum loss reached as high as 10%. This volume loss 
in the lower extremities accounts for most of the muscle atrophy and the blood and 
interstitial fluid shift. Although fluid shift away from the legs influences the size 
of these muscles, this phenomenon alone cannot explain the changes in leg volume 
on MRI. Muscle atrophy appears rapidly, usually between 8 and 11 days of flight, 
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but can appear as early as the fifth day, as observed in one astronaut. Moreover, the 
effects of microgravity differ among muscles, with volume decreasing by 3.9% in 
the calf (the soleus and gastrocnemius) and 6% in the quadriceps femoris.
In addition to the morphological changes, functional alterations are associated 
with structural variations, and the muscular force is known to be reduced after 
spaceflight. In the Skylab 3 mission, it decreased by 20% after 53 days of micrograv-
ity exposure. Muscular electrical activity measured by electromyogram (EMG) had 
a lower EMG amplitude in addition to easy fatigability with a lower resistance.
The main cause of muscular loss is the disappearance of mechanical constraints 
and the subsequent decrease in muscular activity. The reduced muscular activity 
under microgravity is also associated with hypokinesia due to limited movement 
inside the spacecraft, which also can be observed in bedrest studies and animal 
experiments using tail suspension. The structural changes in skeletal muscle are 
also observed by microscopic examination under microgravity, which revealed 
that the proportion of type I red fibers decreased and they were replaced by type II 
white fibers. In 1995, pre- and postflight human muscle biopsies were performed on 
three and five astronauts during 5- and 11-day missions, respectively. In this study, 
the muscle fiber diameter decreased by 15 to 30%, and the number of capillaries 
around the muscle fibers decreased. The proportion of type I fibers changed from 
43 (preflight) to 37% (postflight) after 5-day missions, and that of type II fibers 
changed from 57 to 67%. After 11 days of spaceflight, the proportion of type I fibers 
decreased from 45 to 39%, and that of type II fibers decreased from 55 to 61%, con-
sistent with the animal experiments that demonstrated that gravity can  influence 
genes regulating the protein synthesis of muscle protein degradation enzymes.
These changes were confirmed to be due to both an increase in protein break-
down and decrease in synthesis. Human biochemical examination also revealed a 
higher level of muscle protein degradation, increased level of urinary amino acids, 
and higher level of creatinine. The diet of astronauts is protein-rich, but the deg-
radation process is such that nitrogen losses overcome the gains and the nitrogen 
balance becomes negative.
Recent studies have suggested the mechanism of disuse atrophy of the skeletal 
muscle, especially oxidative stress, to be an important regulator of pathways leading 
to muscle atrophy during periods of disuse. Redox disturbances, such as those 
in skeletal muscle myotubes, increase the expression of key components of the 
proteasome proteolytic system, which is a prominent factor in protein degradation 
in disused muscles.
Another hypothesized mechanism is the degradation of muscle proteins result-
ing from their ubiquitination. These molecular mechanisms underlie protein 
degradation during disuse.
4.2 Countermeasures for muscle loss
In order to prevent muscle loss, several countermeasures were available dur-
ing microgravity exposure in Shuttle missions and continue to be available on the 
ISS. These include aerobic exercise, stretching, strength training, and electrical 
stimulation. Artificial gravity with exercise has been proposed as a potential mea-
sure for muscle loss because ground-based studies confirmed it to be effective, but 
a short-arm centrifuge has not been mounted. In addition to physical stimulation, 
medications, such as antioxidants, growth hormone, growth factors, ubiquitin, 
clenbuterol, anabolic steroids, and amino acids, are candidates against muscle loss.
Aerobic exercise is the most effective countermeasure for maintaining the fast 
twitch red fibers. On the ISS, the combination of an ergometer, treadmill, and the 
Advanced Resistive Exercise Device (ARED) is ideal to maintain muscle power and 
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the morphology of antigravity muscles (empowerment of both fast and slow twitch 
fiber muscles).
Stretching can minimize atrophy by maintaining the muscle as much as possible 
in the stretched condition. In the Russian space program, the penguin suit—a snug 
fitting, full-length, long sleeved jumpsuit made with elastic inserts at the collar, 
waist, wrists, and ankles and along the vertical sides of the suit—loads the body 
along the long axis with an adjustable force of 15–40 kg, while the other elastic 
elements make it possible to adjust the position of the limbs. The angle of the major 
joints, such as the knee and ankle, can be set, allowing the foot to be dorsiflexed, 
which will stretch the soleus. The effects of stretching are not well understood, but 
it is a valid countermeasure considering human physiology.
Strength training by resistance exercise is also employed as a countermeasure 
for muscle loss. Weight training studies recommended a good mix of exercise types 
to be 15% (eccentric), 10% (isometric), and 75% (concentric weight-bearing). The 
most recommended exercise for resistance training is squatting.
Electric stimulation is also expected to increase protein synthesis and prevent 
the decrease in oxidative enzymes inducing disuse atrophy.
4.3 Artificial gravity with exercise
We previously confirmed the effectiveness of artificial gravity in bedrest studies 
[33]. Our results demonstrated that artificial gravity of 1.4 G with ergometric 
exercise maintains the muscle strength and cross-sectional area of the quadriceps 
femoris measured by MRI. Another study revealed that artificial gravity with 
squatting exercise also maintains the function and morphology of the soleus and 
gastrocnemius [38].
5. Bone metabolism system
The main problem of the skeletal system is bone calcium (Ca2+) loss during 
microgravity. The bone becomes fragile during microgravity exposure, which can 
harm an astronaut or cosmonaut even after returning to Earth. Moreover, the risk of 
renal stones is high during long-term missions due to hypercalcemia [39].
Ca2+ plays an essential role in bone structure, contraction of skeletal and cardiac 
muscles, neural transmission, blood coagulation, cell permeability, and hormonal 
signaling. The serum Ca2+ level is well maintained at 8.4–10.2 mg/dL. Ca2+ is 
absorbed from the small intestine (300 mg/day), into the blood, deposited in the 
bone (500 mg/day), and excreted from the kidneys (150 mg/day) or into feces.
In this section, the influences of gravity on bone structure and of hormones on 
bone formation and absorption are described.
5.1 Bone development and restructuring
Gravity influences the long bones of the lower extremities, e.g., the femur, tibia, 
calcaneus, and vertebrae, which support the body in the upright position. Bone 
tissue contains osteocytes, which develop from osteoblasts, and are changed into 
osteoclasts by the action of RANKL (also called osteoclast differentiation factor, 
short for receptor activation of NF-kappa B ligand).
Osteoblasts and osteoclasts are functionally closely related, as is the balance 
between bone formation and bone resorption. Thus, insufficient bone formation 
compared with bone resorption observed in spaceflight reduces the bone mass and 
bone strength, leading to fractures.
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Two hormones, calcitonin and parathormone (PTH), and vitamin D play an 
essential role in Ca2+ metabolism. Calcitonin is secreted from C cells of the thyroid 
gland. The secretion of calcitonin is promoted by an increase in the blood cal-
cium concentration and is suppressed by the decrease in the serum calcium level. 
Calcitonin acts on the calcitonin receptor in osteoclasts to suppress the release of 
Ca2+ from the bone and promotes the deposition of calcium and phosphate on the 
bone. Calcitonin also promotes the excretion of calcium and phosphate into the 
urine. As a result, the serum level of Ca2+ decreases.
PTH is secreted from the parathyroid gland, increasing the release of Ca2+ from 
bone. PTH binds to osteoblasts to increase the expression of RANKL and inhibits 
their secretion of osteoprotegerin (OPG), which competitively binds to RANKL, 
preventing RANKL from interacting with RANK (receptor for RANKL). The bind-
ing of RANKL stimulates osteoclast precursors to fuse, forming new osteoclasts. As 
a result, PTH increases bone resorption, thereby increasing the serum Ca2+ level.
Vitamin D (25-hydroxycholecalciferol) acts on the parathyroid gland and 
suppresses the synthesis and secretion of PTH. The intestinal tract promotes the 
absorption of calcium and phosphorus. Vitamin D is essential for bone formation, 
but its direct action on bone formation remains unclear. It is also necessary for 
the formation of osteoclasts, affects the bone action of PTH, and promotes bone 
resorption itself at a high concentration. In the kidney, vitamin D increases Ca2+ 
reabsorption in the distal tubule and promotes the Ca2+ reabsorption action of PTH.
5.2 Effects of microgravity on bone metabolism
The main factor of bone metabolism is mechanical impact. Gravity creates 
weight and is responsible for the pressure exerted on a large part of the skeleton, 
resulting in a mechanical impact on bones. These gravitational impacts provide 
mechanical constraints on the femurs, tibias, calcaneus, and vertebrae. Thus, 
decalcification and bone loss are observed as the result of bone resorption, and the 
disappearance of gravity from the body axis components induces bone loss and 
resultant osteoporosis [2, 40].
5.3 Effects of spaceflight on bone metabolism
In microgravity conditions, decalcification was observed in 12 of the astronauts 
on the Gemini and Apollo 7 and 8 flights in 1969 [8]. Based on bone density mea-
sured using X-rays, the bone Ca2+ loss was 3.2%.
The bone mineral density was measured before and after the Mir program. The 
changes were as follows: +0.6% in the skull, +0.1% in the arm, −1.07% in the spine, 
−1.35% in the pelvis, −1.16% in the femoral neck, −1.58% in the trochanter major, 
−1.25% in the tibia, and −1.50% in the calcaneus per month, with comparable 
results from the ISS [41]. The most affected bones during spaceflight are weight-
bearing bones, e.g., the pelvis (os coxae), the trochanter major of the femur, the 
femoral neck, the tibia, and the calcaneus.
Mir studies using dual photonic densitometry demonstrated a mean decrease 
in bone mineral density of approximately 0.3%/month in the cortical bone and up 
to 0.9%/month in cancellous tibial bone. Decalcification only occurs in the weight-
bearing bones, and demineralization is correlated with mission duration. During 
spaceflight, hypercalcemia and hyperphosphatemia develop due to demineraliza-
tion, and Ca2+ excretion into the urine increases before stabilization at around the 
30th day of flight [42].
The National Aeronautics and Space Administration (NASA) of the United 
States documented a bone mineral loss rate/month of 1–2% during spaceflight 
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(https://science.nasa.gov/science-news/science-at-nasa/2001/ast01oct_1), and 
bone density loss of 5–6% was reported in Apollo 15 crewmembers [43]. Bone loss is 
influenced by the spaceflight duration.
Tail suspension studies on rats demonstrated that simulated microgravity 
reduces bone formation, alters the Ca2+ balance, and inhibits the proliferation 
and differentiation of osteoprogenitor cells [44]. Osteocytes can also be affected 
by unloading stimulus in a bioreactor, with high expression of inhibitors of bone 
formation (sclerotin) and stimulators of bone resorption (RANKL) [45].
Osteoporosis can be irreversible. After returning to Earth without appropriate 
rehabilitation, the bone may be unable to return to normal activity under loads 
and may be weaker, easily inducing fractures. Reloading after a period of a week 
can ameliorate bone weakness, but even 2 weeks of bone restoration was not 
satisfactory. The length of spaceflight influences the bone density loss; however, 
another report stated that the bone loss at 1 month continued to increase after 
6 months, suggesting that the length of spaceflight does not determine the bone 
density loss [42].
5.4 Effects of mechanical impact on hormonal influence
Wolff ’s law characterizes how the bone adapts to functionally withstand its 
mechanical environment [46]; however, several studies found that mechanical 
loading per se is not the direct stimulus for bone remodeling [47–51].
Then what are the effects of mechanical impact on calcitonin? Calcitonin 
receptors were not observed on osteoblasts [52] but were present on osteoclasts [53] 
and osteocytes [54]. Calcitonin was reported to inhibit apoptosis of osteoblasts and 
osteocytes, demonstrating a potential indirect influence on bone formation. These 
data confirmed that mechanical impact is not directly related to bone formation.
One notable property of PTH is that although chronic increases in PTH levels 
increase bone resorption, intermittent stimulation accelerates bone formation. PTH 
stimulates osteoclast formation by binding to PTH receptor 1 on stromal/osteoblas-
tic cells and thereby increases the production of receptor activator of RANKL and 
macrophage colony-stimulating factor (M-CSF) and suppresses the RANKL decoy 
receptor osteoprotegerin. Moreover, PTH controls the production of osteoblasts 
through actions on osteocytes through Wnt signaling in osteoblastogenesis [55].
The action of osteocytes, which can directly sense a mechanical unloading 
stimulus, increased the expression of both inhibitors of bone formation (SOST/
sclerotin) and stimulators of bone resorption (RANKL) through Wnt signaling [45]. 
These results support the hypothesis that intermittent mechanical impacts induce 
osteocyte action, which inhibits bone formation and stimulates bone resorption, 
and that an intermittent increase in PTH controls the production of osteoblasts.
5.5 Sympathetic alteration of bone metabolism during spaceflight
It has been reported that sympathetic neural traffic to bone inhibits the function 
of osteoblast and increases that of osteoclast, thus facilitating bone loss. Possible 
roles of the sympathetic nervous system in the mechanisms of bone loss in humans 
exposed to long-term spaceflight will be discussed.
Prolonged exposure to microgravity in space for 14 days increased sympathetic 
neural traffic in humans based on results from the Neurolab mission [14, 56–58], 
with comparable increases in noradrenaline spillover and clearance in space [14]. 
Concordant results were obtained during simulated microgravity, including dry 
immersion [28] or head-down bedrest [17]. In general, elderly people have a low 
bone density and high sympathetic neural traffic to muscles [59]. Our preliminary 
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study demonstrated that changes in sympathetic neural traffic to muscles after 
long-term bedrest of 20 days were significantly correlated with changes in the 
urinary secretion level of deoxypyridinoline [25, 60], which is used as a specific 
marker of bone resorption [61]. Based on these findings, exposure to prolonged 
microgravity may increase sympathetic neural traffic to the bone, which increases 
the noradrenaline level, thereby inhibiting osteogenesis and facilitating osteolysis 
through β-receptors to induce bone mineral loss.
5.6 Countermeasures for space-related osteoporosis
1. Physical factors
Exercise during weightlessness has been incorporated into the present counter-
measure programs; however, exercise alone cannot prevent bone loss. The current 
exercise program for the ISS is a combination of aerobic and resistive exercise for 
2.5 hours, 6 days/week. Data from spaceflight revealed that bone loss occurs mainly 
in the femur, tibia, calcaneus, and vertebrae. Therefore, exercise should be concen-
trated on these bones, and impact loading should be primarily provided rather than 
static loading [62].
2. Pharmacological factors
As bone mass is sufficient at the onset of the spaceflight, the optimal strategy for 
the pharmacotherapy against bone loss is the prevention of bone loss, not the accel-
eration of bone formation, when loading is removed during spaceflight. Several 
drugs have been proposed to prevent bone loss under microgravity.
3. Bisphosphonates
Bisphosphonates have two phosphonate (PO3) groups and are similar in struc-
ture to pyrophosphate. They bind to hydroxyapatite in bone matrix and prevent 
bone loss by inhibiting osteoclastic bone resorption. Bisphosphonates have been 
demonstrated to be effective in preventing bone loss during bedrest studies [63–66]. 
Among several types of bisphosphonates, pamidronate has been confirmed to sup-
press bone mineral loss and to prevent the formation of renal stones during bedrest 
studies [67].
In 2010, LeBlanc and Matsumoto [68] proposed an experiment for the effective-
ness of bisphosphonate as a countermeasure to spaceflight-induced bone loss. The 
astronauts chose either oral administration of alendronate at 70 mg once per week 
or intravenous administration of zoledronate at 4 mg before the flight, and their 
bone densities were examined by DXA, QCT, and pQCT, and bone metabolism 
markers, including bone formation and resorption markers, and renal stone forma-
tion were assessed. One of the co-investigators (Ohshima) reported successful 
suppression of spaceflight-induced bone loss and renal stone formation (Ohshima, 
personal communication).
The disadvantages of bisphosphonates are local irritation of the upper gastroin-
testinal (GI) tract and poor absorption from the GI tract. Therefore, the oral admin-
istration of bisphosphonates requires drinking 200 mL of water while remaining 
in an upright posture for at least 30 min until after their first meal of the day to 
facilitate delivery to the stomach. This poses a problem as there is no upright pos-
ture in space due to microgravity. Another potential problem is osteonecrosis of the 
maxilla and the mandible, although the incidence is low [69]. These osteonecrotic 
or osteolytic phenomena always accompany physiological stress (mastication), 
iatrogenic trauma (tooth extraction/denture injury), or tooth infection [70, 71].
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Bisphosphonates are difficult to metabolize, and high concentrations of them are 
maintained in the bones for long periods. As bone formation is closely coupled with 
bone turnover, long-term use of the compound with resultant suppression of bone 
turnover can compromise healing of even physiological microinjuries within the 
bone. Osteonecrosis of the maxilla and mandible likely results from the inability of 
the hypodynamic and hypovascular bone to meet the increased demand for repair 
and remodeling because several alterations are associated with this necrosis.
4. Parathormone
Parathormone has anabolic effects on the bone and also functions in the kidney 
to stimulate the reabsorption of Ca2+ and increase the synthesis of vitamin D. In 
this sense, parathormone may stimulate bone formation, increase vitamin D 
synthesis, and stimulate Ca2+ reabsorption. As suppressing bone reabsorption is 
favorable for stimulating bone formation during spaceflight, the administration of 
parathormone is strategically unfavorable.
In conclusion, it is favorable to administer bisphosphonate orally under artificial 
gravity with exercise in order to prevent osteoporosis in space. Monitoring the blood 
and urine samples on the ISS or spacecraft by a simple method is necessary to assess 
the effectiveness of the countermeasure.
6. Immunology and hematology
6.1 Space anemia
The circulatory blood volume is 5 L on average and contains plasma and cellular 
components, including erythrocytes, leukocytes (neutrophils, eosinophils, baso-
phils, and lymphocytes), and platelets [72–74]. Among them, reduction in cellular 
components, especially erythrocytes (RBC), is associated with anemia, whereas the 
function of leukocytes is related to immunological response.
In the early stages of space development, cases of “space anemia” (hematocrit 
reduction) were reported on Gemini, Apollo, Skylab, and Shuttle missions and in the 
cosmonauts in the Salyut and Mir missions. However, in spaceflight, microgravity 
causes cephalad fluid shift, meaning this “space anemia” was actually a misinterpre-
tation of symptoms. The true effects of microgravity can be measured through the 
total RBC count calculated from the hematocrit and plasma volume measurements. 
In this way, “space anemia” corresponded to a reduction in the total RBC count.
After 10 days aboard Spacelab-1, the total RBC count was reduced by 9% and 
by 15% after several weeks. After returning to Earth, the total RBC count did not 
recover even after 6 weeks and, in the case of Skylab astronauts, had not recovered 
after more than 3 months.
This suggested that microgravity is responsible for “space anemia,” and many 
investigations were carried out to reveal whether anemia is the result of an increase 
in RBC destruction or a decrease in their production. Using labeled RBC by the 
uptake of 14C glycine, RBC destruction was found to be three times greater in rats 
having flown aboard Cosmos-782 than in the control rats. On the other hand, 
reduced RBC production is unlikely because the number of stem cells measured by 
the number of cellular colonies that developed in vitro from samples of bone mar-
row taken from rats that flew aboard the Soviet Biosatellite—2044 for 14 days—was 
unchanged.
Human studies carried out by [75] on Shuttle missions for 9 to 14 days dem-
onstrated that space anemia is due mainly to a lower production of RBC, causing 
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increased plasma volume, reduced hemoglobin concentration, and increased serum 
erythropoietin. This reflects a decrease in the RBC life span and slower production.
Rizzo et al. [76] analyzed the cause of the shortened RBC life span and reported 
altered cell membrane composition and an increase in lipid peroxidation products. 
They suggested that antioxidant defense systems in the erythrocytes were induced, 
with a significant increase in glutathione content.
The mechanism underlying anemia was also confirmed by measuring the 
erythropoietin (EPO) level [77]. Radioimmunoassay revealed that the EPO level 
decreases after 24 hours of flight and is reduced by 30–40% on the third day com-
pared with preflight levels. This low secretion of EPO will inhibit RBC maturation 
and cause hemolysis due to suppressed erythropoiesis.
Other changes in leukocytes (WBC) are in their polymorphonuclear charac-
teristics. The composition of WBC is changed such that there is a slight increase in 
neutrophils and decrease in eosinophils. The percentage of lymphocytes, especially 
T cells, decreases, whereas that of monocytes slightly increases. These changes 
quickly disappear upon returning to 1 G on Earth.
6.2 Immunological changes during weightlessness
Recent studies confirmed dysregulation of the immunological response in 
humans and the reactivation of latent herpes virus, which persisted for the duration 
of a 6-month orbital spaceflight [78]. Blood samples from ISS crew members dem-
onstrated that long exposure to microgravity reduced their T lymphocyte counts, 
suggesting the attenuation of cytotoxic function and viral reactivation in the space 
environment.
As the immune system is highly sensitive to different types of stressors, includ-
ing psychological, physical, and local environmental stressors (e.g., oxidative and 
radiation exposure), exposure to the space environment suppresses T helper cells, 
which leads to susceptibility to viruses.
7.  Artificial gravity as a total countermeasure for spaceflight 
deconditioning
For human space voyages lasting several years, such as those envisioned for the 
exploration of Mars, astronauts will be at risk of catastrophic consequences should 
any of the systems that provide air, water, food, or thermal protection fail. Beyond 
that, astronauts will face serious health and/or safety risks resulting from marked 
physiological deconditioning associated with prolonged weightlessness [1, 79]. The 
principal physiological deconditioning risks are related to physical and functional 
deterioration, and the loss of regulation of the several systems, including blood 
circulation, decreased aerobic capacity, musculoskeletal systems, and altered 
sensorimotor system performance. These physiological effects of weightlessness are 
generally adaptive to spaceflight and present a hazard only following G transitions 
upon returning to Earth or landing on another planet [80]. Among them, bone 
mineral metabolism will be greatly affected during prolonged spaceflight.
7.1 Why artificial gravity
Space biomedical researchers have been working for many years to develop 
“countermeasures” to reduce or eliminate the deconditioning associated with 
prolonged weightlessness. Intensive and sustained aerobic exercise on a treadmill, 
bicycle, or rowing machine coupled with intensive resistive exercise has been 
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used on US and Russian spacecraft to minimize these problems. The procedures 
were uncomfortable and excessively time-consuming for many astronauts, and 
their effectiveness for maintaining bone, muscle, and aerobic fitness has not 
been demonstrated due in part to the low reliability of the devices flown to date. 
Furthermore, they have had inconsistent effects on postflight orthostatic hypoten-
sion or sensorimotor adaptive changes. With the exception of fluid loading before 
reentry, other countermeasures (e.g., diet, lower body negative pressure, or wearing 
a “penguin suit” to force joint extension against a resistive force) either have been 
marginally effective or presented an inconvenience or hazard.
To succeed in the near-term goal of a human mission to Mars during the second 
quarter of this century, the human risks associated with prolonged weightlessness 
must be mitigated well beyond our current capabilities. Indeed, during nearly 
45 years of human spaceflight experience, including numerous long-duration 
missions, no single countermeasure or combination of countermeasures that is 
completely effective has been developed. Current operational countermeasures 
have not been rigorously validated and have not fully protected any long-duration 
(>3 months) astronauts in low Earth orbit. Thus, it is unlikely that they will suf-
ficiently protect astronauts journeying to Mars and back over a 3-year period.
Although improvements in exercise protocols, changes in diet, or pharmaceuti-
cal treatments of individual systems may be of value, they are unlikely to eliminate 
the full range of physiological deconditioning. Therefore, a complete research and 
development program aimed at substituting the missing gravitational cues, and 
loading in space is warranted.
The urgency of exploration-class countermeasures is compounded by the lim-
ited availability of flight resources for validating a large number of system-specific 
countermeasure approaches. Furthermore, recent evidence of the rapid degradation 
of pharmaceuticals flown aboard long-duration missions, putatively because of 
radiation effects, raises concerns regarding the viability of some promising coun-
termeasure development results. Although the rotation of a Mars-bound spacecraft 
will not be a panacea for all human risks of spaceflight (artificial gravity cannot 
solve the problems associated with radiation exposure, isolation, confinement, and 
environmental homeostasis), artificial gravity does offer significant promise as an 
effective, efficient, multi-system countermeasure against the physiological decon-
ditioning associated with prolonged weightlessness. Virtually all of the identified 
risks associated with cardiovascular deconditioning, myatrophy, bone loss, neu-
rovestibular disturbances, space anemia, immune compromise, and neurovegeta-
tive state may be alleviated by sufficient artificial gravity.
7.2 Why artificial gravity with exercise
Although a short-radius centrifuge has been proposed several times, loading 
with artificial gravity has not been demonstrated to be effective at preventing 
spaceflight deconditioning on its own. Making a human-powered short-arm cen-
trifuge is an effective method to create exercise loads for astronauts. Considering 
the size of the ISS, it is appropriate to employ a short-radius centrifuge rather 
than a large-radius human centrifuge; however, it may be beneficial to rotate the 
spacecraft itself to provide the artificial gravity for long-duration spaceflight such 
as Mars expeditions.
In 1999, Iwase proposed the creation of artificial gravity by ergometric exercise, 
and it was installed at Nagoya University [33]. Several studies were performed using 
this short-radius centrifuge with an ergometer. In 2002, a bedrest study was car-
ried out to evaluate the effectiveness of artificial gravity with ergometric exercise. 
In 2005, the facility was moved to Aichi Medical University, and bedrest studies 
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were performed to finalize the protocol. This daily AG-EX step-up protocol was 
confirmed to be effective at preventing cardiovascular, musculoskeletal, and bone 
metabolism deconditioning in 2006, whereas the alternate-day (every-other-day) 
protocol (loading the AG-EX every other day) did not improve the spaceflight 
deconditioning associated with the microgravity exposure analogue of −6° head-
down bedrest.
The authors applied for the installation of a short-radius centrifuge facility on 
the ISS and proposed it as a method to prevent spaceflight deconditioning, includ-
ing bone loss. This project, Artificial Gravity with Ergometric Exercise (AGREE 
project), was promising to prevent space deconditioning during spaceflight, but it 
was canceled halfway through (Figure 1).
8. Conclusion and summary
Several deconditioning states in the neurovestibular, cardiovascular, ocular, 
musculoskeletal, bone metabolic, hematological and immunological, and central 
nervous systems have been documented, and efforts to ameliorate the symptoms 
have been made. In the near future, space medicine will play an increasingly impor-
tant role in missions to the Moon and Martian expeditions as well as in future deep 
space exploration.
Historically, space medicine examined early adaptation to microgravity and 
early readaptation to the terrestrial 1 G state. However, the philosophy of the 
authors is to avoid adaptation to microgravity using artificial gravity. Under this 
scenario, short exposure to microgravity is permitted, but longer adaptation will be 
unnecessary. With this philosophy, the authors believe that the humans will achieve 
safe and comfortable spaceflight without deconditioning.
Figure 1. 
Structure of the device of artificial gravity with exercise for AGREE project 2012.
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